PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Alexander Drilon, MD - Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors

Mark J. Levis, MD, PhD - Finding the Key to Better Outcomes in FLT3-Mutated AML: Guidance on New Evidence With Next-Gen FLT3 Inhibitors

Ruben A. Mesa, MD, FACP - Taking the Targeted Option for Myelofibrosis: Insights on Modern JAKi Platforms and Emerging Therapeutics

Prof. Dr. Martin Dreyling - Taking the Leap in MCL: New Opportunities With BTK Inhibitors and Other Innovative Strategies

Prof. Thomas Cluzeau, MD, PhD - “Intensity” With Efficacy in Acute Myeloid Leukemia (AML): Developing Modern, Intensive Upfront Platforms for Challenging Disease Presentations

Stephen V. Liu, MD - Amplifying the ADC Advantage: How to Fulfill the Potential of Antibody–Drug Conjugates as the Next Frontier in Precision Lung Cancer Care

Guillermo Garcia-Manero, MD - The Team Takes Command in MDS: Guidance on Diagnostic and Treatment Principles for Risk-Based Care and Beyond

Steven W. Pipe, MD - Leading the Change in Hemophilia A: Guidance on Enhancing Prophylactic Care With Innovative EHL FVIII Products

Pasi A. Jänne, MD, PhD - A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLC: The Latest Evidence and Practical Guidance for Biomarker Testing and Individualized Treatment Selection and Sequencing

Robert Z. Orlowski, MD, PhD - The New ABCs of Myeloma Care: Enhancing Outcomes With CD38 Antibodies, BCMA Immunotherapy, and Unique Bispecific Platforms